Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
INMB vs EQ: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
EQ Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)
EQ Overall Winner
6-Pillar Tally: INMB 1 – 4 EQ (1 Tie)
Matrix Metrics: INMB 2 – 6 EQ
As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over INmune Bio Inc. (INMB) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). INMB carries a Unified Composite Score of 45.4/100 (HOLD) at $0.89 (N/M Forward P/E, 0.0% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin).
- Growth vs. Quality Trade-Off: EQ earns the overall head-to-head edge with a stronger Unified Composite Score (48.0/100 HOLD vs. INMB 45.4/100 HOLD) and 1.53β · 93% Vol risk profile, whereas INMB leads top-line expansion (+257.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: INMB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.4); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About INMB vs EQ
INMB
INmune Bio Inc. Common stock
$0.89
-13.19% 1D
Market Cap
$31.9M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
2.70β · 85% Vol
Unified Composite Score
45.4
HOLD
Tech 30.0
Fund 58.0
Flow 70.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
EQ
Head-to-Head Winner
Equillium, Inc. Common Stock
$1.12
+1.82% 1D
Market Cap
$90.6M
TTM Revenue
$4.4M
Forward P/E
1.5x
Beta / 30D Vol
1.53β · 93% Vol
Unified Composite Score
48.0
HOLD
Tech 30.0
Fund 51.0
Flow 63.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (INMB 1 – 4 EQ)
1. Valuation Multiples
EQ
Forward P/E
N/M
1.5x
Trailing P/E
N/M
1.5x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
7.7x
2. Growth & Scale
EQ
Revenue Growth (YoY)
+257.1%
-52.3%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$4.4M
Market Cap
$31.9M
$90.6M
3. Profitability & Quality
EQ
Gross Margin
N/A
100.0%
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-76.7%
-59.0%
4. Balance Sheet & Cash Flow
EQ
Cash Generation (TTM)
-$13M
-$20M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$15M Net Cash
$57M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
INMB
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
200.2% (61st %ile)
261.3% (100th %ile)
Put/Call OI Skew
0.53x (Call-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: INMB (2) vs EQ (6)| Institutional Metric | INMB | EQ | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $31.9M | $90.6M | EQ | |
| Trailing P/E Ratio | N/M | 1.5x | EQ | |
| Forward P/E Ratio | N/M | 1.5x | EQ | |
| Revenue Growth (YoY) | +257.1% | -52.3% | INMB | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -76.7% | -59.0% | EQ | |
| 52-Week Range Position | 0% ($1–$3) | 11% ($1–$4) | EQ | |
| Beta / 30D Volatility | 2.70β · 85% Vol | 1.53β · 93% Vol | INMB | |
| Unified Institutional Score | 45.4 / 100 (HOLD) | 48.0 / 100 (HOLD) | EQ | |
| Trailing 12M Revenue (USD) | N/A | $4.4M | Scale | |
| Gross Profit Margin (TTM) | N/A | 100.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 7.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$13M ($15M Net Cash) | -$20M ($57M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
EQ +23.34 pp
3M Horizon
EQ +9.94 pp
6M Horizon
INMB +11.41 pp
1Y Horizon
EQ +52.39 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | INMB Revenue | EQ Revenue | INMB Op. Margin | EQ Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | $0M | N/A | -111163.6% | N/A | INMB |
| FY2021 | $0M | N/A | -16106.6% | N/A | INMB |
| FY2022 | $0M | $20M | -6938.8% | -393.9% | EQ |
| FY2023 | $0M | $40M | -19187.7% | -40.2% | EQ |
| FY2024 | $0M | $40M | -304535.7% | -20.1% | EQ |
| FY2025 | $0M | N/A | -94766.0% | N/A | INMB |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
INMB
BREAKDOWN
Current IV
200.2%
IV Percentile
61st %ile
Put/Call OI Skew
0.53x (Call-Skewed)
IV Regime
Elevated (60th–80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact INMB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
EQ
UNCLASSIFIED
Current IV
261.3%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
INMB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
EQ Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ INMB vs EQ Key Questions & Quantitative Answers
As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over INmune Bio Inc. (INMB) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). INMB carries a Unified Composite Score of 45.4/100 (HOLD) at $0.89 (N/M Forward P/E, 0.0% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: EQ earns the overall head-to-head edge with a stronger Unified Composite Score (48.0/100 HOLD vs. INMB 45.4/100 HOLD) and 1.53β · 93% Vol risk profile, whereas INMB leads top-line expansion (+257.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: INMB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.4); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EQ leads the Growth & Scale pillar: INMB posts +257.1% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EQ at -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), INMB cumulative revenue shifted N/A while EQ shifted +100.0%. In operating R&D and SG&A reinvestment, INMB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EQ.
EQ screens cheaper on headline valuation multiples. INMB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 7.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INMB (-76.7% ROE) versus EQ (-59.0% ROE) capital efficiency.
In options market volatility and institutional positioning, INMB carries 200.2% implied volatility (61st %ile, Elevated (60th–80th %ile)), a 0.53x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.70β · 85% Vol realized risk). By comparison, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 93% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
EQ vs INMB · Reverse Pair
EQ vs ECOR
· Sector Peer
EQ vs CRVS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal